|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.790 HKD | +1.91% |
|
+5.52% | -22.65% |
| 06:53am | Sino Biopharmaceutical Plans HK$2 Billion Stock Buyback | MT |
| 30/05 | Sino Biopharmaceutical Limited Announces Approval For Marketing of Naldemedine For Opioid-Induced Constipation In Adults | CI |
| Fiscal Period: December | 2016 | 2017 (CNY) | 2018 (CNY) | 2019 (CNY) | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 1.06TCr | 1.21TCr | 945.19Cr | 956.96Cr | 1.22TCr | |||||
Short Term Investments | 57Cr | - | 155.33Cr | 22Cr | 41Cr | |||||
Trading Asset Securities, Total | 465.57Cr | 485.54Cr | 311.3Cr | 502.77Cr | 1.04TCr | |||||
Total Cash And Short Term Investments | 1.58TCr | 1.69TCr | 1.41TCr | 1.48TCr | 2.3TCr | |||||
Accounts Receivable, Total | 422.07Cr | 464.34Cr | 459.62Cr | 501.26Cr | 600.91Cr | |||||
Other Receivables | 131.66Cr | 157.53Cr | 160.24Cr | 178.75Cr | 209.11Cr | |||||
Total Receivables | 553.73Cr | 621.87Cr | 619.86Cr | 680.01Cr | 810.02Cr | |||||
Inventory | 193.77Cr | 232.88Cr | 199.35Cr | 237.31Cr | 225.67Cr | |||||
Prepaid Expenses | 23Cr | 47Cr | 58Cr | 69Cr | 114.67Cr | |||||
Other Current Assets, Total | - | - | 91Cr | - | - | |||||
Total Current Assets | 2.35TCr | 2.59TCr | 2.38TCr | 2.47TCr | 3.45TCr | |||||
Gross Property Plant And Equipment | 1.25TCr | 1.39TCr | 1.54TCr | 1.67TCr | 1.75TCr | |||||
Accumulated Depreciation | -397.48Cr | -460.71Cr | -548.06Cr | -645.88Cr | -728.46Cr | |||||
Net Property Plant And Equipment | 851.61Cr | 925.12Cr | 991.22Cr | 1.03TCr | 1.02TCr | |||||
Long-term Investments | 2.52TCr | 2.44TCr | 2.52TCr | 2.63TCr | 2.35TCr | |||||
Goodwill | 65Cr | 66Cr | 68Cr | 92Cr | 349.62Cr | |||||
Other Intangibles, Total | 29Cr | 28Cr | 25Cr | 27Cr | 19Cr | |||||
Deferred Tax Assets Long-Term | 33Cr | 51Cr | 57Cr | 52Cr | 51Cr | |||||
Deferred Charges Long-Term | 77Cr | 97Cr | 198Cr | 187.34Cr | 336.39Cr | |||||
Other Long-Term Assets, Total | 130.78Cr | 207.9Cr | 123.02Cr | 52Cr | 29Cr | |||||
Total Assets | 6.05TCr | 6.41TCr | 6.36TCr | 6.54TCr | 7.6TCr | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 179.47Cr | 188.36Cr | 133.47Cr | 149.75Cr | 153.16Cr | |||||
Accrued Expenses, Total | 514.58Cr | 629.92Cr | 671.58Cr | 765.12Cr | 1.03TCr | |||||
Short-term Borrowings | 14Cr | 14Cr | 14Cr | - | - | |||||
Current Portion of Long-Term Debt | 652.06Cr | 966.34Cr | 1.11TCr | 760.21Cr | 839.54Cr | |||||
Current Portion of Leases | 6.45Cr | 6.04Cr | 7.15Cr | 2.83Cr | 2.33Cr | |||||
Current Income Taxes Payable | 10Cr | 11Cr | 27Cr | 32Cr | 70Cr | |||||
Unearned Revenue Current, Total | 24Cr | 31Cr | 28Cr | 25Cr | 39Cr | |||||
Other Current Liabilities | 134.4Cr | 168.97Cr | 265.83Cr | 220.6Cr | 384.23Cr | |||||
Total Current Liabilities | 1.53TCr | 2.02TCr | 2.26TCr | 1.96TCr | 2.52TCr | |||||
Long-Term Debt | 521.25Cr | 393.39Cr | 107.44Cr | 199.68Cr | 758.4Cr | |||||
Long-Term Leases | 32Cr | 32Cr | 30Cr | 8.34Cr | 6.73Cr | |||||
Unearned Revenue Non Current | 67Cr | 75Cr | 55Cr | 56Cr | 62Cr | |||||
Deferred Tax Liability Non Current | 88Cr | 83Cr | 78Cr | 24Cr | 29Cr | |||||
Other Non Current Liabilities | 38Cr | 13Cr | 13Cr | 20Cr | 16Cr | |||||
Total Liabilities | 2.28TCr | 2.61TCr | 2.54TCr | 2.26TCr | 3.39TCr | |||||
Common Stock, Total | 42Cr | 41Cr | 41Cr | 41Cr | 41Cr | |||||
Additional Paid In Capital | 1.26TCr | 1.25TCr | 1.24TCr | 1.24TCr | 1.23TCr | |||||
Retained Earnings | 2.72TCr | 2.84TCr | 2.93TCr | 2.53TCr | 2.5TCr | |||||
Treasury Stock | -69Cr | -143.25Cr | -176.97Cr | -297.48Cr | -295.12Cr | |||||
Comprehensive Income and Other | -922.79Cr | -1.01TCr | -994.85Cr | -318Cr | -407.9Cr | |||||
Total Common Equity | 3.03TCr | 2.97TCr | 3.05TCr | 3.2TCr | 3.07TCr | |||||
Minority Interest | 743.79Cr | 819.65Cr | 769.55Cr | 1.08TCr | 1.14TCr | |||||
Total Equity | 3.77TCr | 3.79TCr | 3.82TCr | 4.28TCr | 4.21TCr | |||||
Total Liabilities And Equity | 6.05TCr | 6.41TCr | 6.36TCr | 6.54TCr | 7.6TCr | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 1.87TCr | 1.85TCr | 1.83TCr | 1.79TCr | 1.79TCr | |||||
ECS Total Common Shares Outstanding | 1.87TCr | 1.85TCr | 1.83TCr | 1.79TCr | 1.79TCr | |||||
Book Value / Share | 1.62 | 1.61 | 1.66 | 1.78 | 1.71 | |||||
Tangible Book Value | 2.94TCr | 2.88TCr | 2.95TCr | 3.08TCr | 2.7TCr | |||||
Tangible Book Value Per Share | 1.57 | 1.56 | 1.61 | 1.72 | 1.51 | |||||
Total Debt | 1.23TCr | 1.41TCr | 1.27TCr | 971.05Cr | 1.61TCr | |||||
Net Debt | -354.04Cr | -280.36Cr | -140.18Cr | -510.74Cr | -689.15Cr | |||||
Debt Equivalent Oper. Leases | 103.45Cr | 97Cr | 111.9Cr | 216.31Cr | 266.63Cr | |||||
Minority Interest, Total (Incl. Fin. Div) | 743.79Cr | 819.65Cr | 769.55Cr | 1.08TCr | 1.14TCr | |||||
Equity Method Investments, Total | 1.43TCr | 1.32TCr | 1.22TCr | 162.01Cr | 163.71Cr | |||||
Account Code - Inventory Valuation | 6 | 6 | 6 | 6 | 6 | |||||
Inventories - Raw Materials, Total | 50Cr | 68Cr | 46Cr | 59Cr | 66Cr | |||||
Inventories - Work In Process, Total | 38Cr | 94Cr | 53Cr | 54Cr | 60Cr | |||||
Inventories - Finished Goods, Total | 98Cr | 58Cr | 88Cr | 110.06Cr | 91Cr | |||||
Inventories - Others | 8.44Cr | 14Cr | 13Cr | 14Cr | 8.87Cr | |||||
Buildings, Total | 357.11Cr | 387.06Cr | 424.8Cr | 501.58Cr | 537.31Cr | |||||
Machinery, Total | 613.18Cr | 669.18Cr | 762.8Cr | 843.29Cr | 886.14Cr | |||||
Full Time Employees | 25.58T | 26.27T | 25.81T | 24.38T | 21.44T | |||||
Accumulated Allowance for Doubtful Accounts (Supple) | 2.6Cr | 3Cr | 2.64Cr | 13Cr | 48Cr |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















